


ISPOR 9th Annual European Congress

"ASKING CRITICAL QUESTIONS"



28-31 OCTOBER 2006 / RADISSON SAS FALCONER HOTEL AND CONFERENCE CENTER / COPENHAGEN, DENMARK

Early Registration Deadline: 19 September 2006



PROGRAM

Congress Program Committee Chairs:

Program Planning Committee Co-Chairs:

Ivar Sønbo Kristiansen MD, MPH, PhD, Professor, Institute of Health, University of Oslo, Oslo, Norway; **Bengt Jönsson PhD**, Professor of Health Economics, Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden

Contributed Issues Panel Committee

Co-Chairs: Chris Bingefors MSc, PhD, Associate Professor, Research Director, Biomedical Centre, Uppsala University, Uppsala, Sweden; **Kjeld Møller Pedersen PhD**, Professor of Health Economics and

Health Policy, Department of Public Health, Health Economics, University of Southern Denmark, Odense C, Denmark

Contributed Research Review Committee

Co-Chairs: Kim Brøsen, Professor, Clinical Pharmacology, University of Southern Denmark, Odense C, Denmark; **Harri Sintonen**, Professor of Health Economics, Dept. of Public Health, University of Helsinki, Helsinki, Finland; **Palle Mark Christensen, MD, PhD**, University of Southern Denmark, Odense C, Denmark

Contributed Workshop Committee Co-Chairs:

Kjeld Møller Pedersen PhD, Professor of Health Economics and Health Policy, Department of Public Health, Health Economics, University of Southern Denmark, Odense C, Denmark; **Chris Bingefors, MSc, PhD**, Associate Professor, Research Director, Biomedical Centre, Uppsala University, Uppsala, Sweden

Special Event: Terkel Christiansen, Professor IST - Health Economics, University of Southern Denmark, Odense C, Denmark

POSTER SESSION I:

Sunday, 29 October

Set-up: 11:30 - 12:00

Poster Display Hours: 12:00 - 20:00

Author Presentation Hour: 18:00 - 19:00

Dismantle: 20:00 - 20:30

POSTER SESSION II:

Monday, 30 October

Set-up: 7:30 - 8:00

Poster Display Hours: 8:00 - 19:30

Author Presentation Hour: 18:00 - 19:00

Dismantle: 19:30 - 20:00

POSTER SESSION III:

Tuesday, 31 October

Set-up: 7:30 - 8:00

Poster Display Hours: 8:00 - 16:00

Author Presentation Hour: 12:00 - 13:00

Dismantle: 16:00 - 16:30



CONGRESS LOCATION:

Radisson SAS Falconer Hotel
Falkoner Alle 9,
Copenhagen F, DK-2000, Denmark
Telephone +45 38 15 80 01
Fax +45 38 15 80 02

RECEPTION at the COPENHAGEN TOWN HALL – ISPOR Networking Event

Open to all Congress Registrants

Monday, 30 October 2006 20:00 - 21:30

Invitation letters found in your registration packet are required for entrance

***Reception compliments of the Copenhagen City Council & transportation compliments of ISPOR**
(Buses will depart the Radisson SAS Falconer beginning at 19:30 and will run continuously until 22:30)*

HOTEL RESERVATIONS:

Phone: +45 3815 6500
Fax: +45 3815 6501
Toll free: Europe: 00800 3333 3333
US: (800) 333-3333
E-mail: reservations.falconer.copenhagen@radissonsas.com
http://www.ispor.org/congresses/denmark1006/hotel_info.asp

TRANSPORTATION:

The Congress venue is located in Frederiksberg, close to the city center of Copenhagen and conveniently served by the Metro (a 2 minute walk). Copenhagen International Airport is 11km (a 25 minute drive) from the city center.



ISPOR 9th Annual European Congress "ASKING CRITICAL QUESTIONS"

28-31 OCTOBER 2006 / COPENHAGEN, DENMARK



SHORT COURSE PROGRAM

SATURDAY, 28 October 2006
(All Day) 8:00 - 17:00

Pharmacoeconomic / Economic Methods Bayesian Methods for Decision-Makers

Faculty: Lieven Annemans PhD, MSC, Health Economist Ghent University, Senior Consultant Global Health Economic, HEDM and IMS Health, Brussels, Belgium

Course Description: This course shows how to incorporate pharmacoeconomics into study design and data analysis. Participants learn to collect and calculate the costs of different alternatives, determine the economic impact of clinical outcomes, and identify, track and assign costs to different types of health care resources. Different pharmacoeconomic models and techniques will be demonstrated and practiced. Decision analysis, sensitivity analysis, and discounting, will be demonstrated and practiced. Participants will also learn to compare and evaluate interventions. *This course is for those with little or no experience with PE.*

SATURDAY, 28 October 2006
(Morning) 8:00 - 12:00

Use of Pharmacoeconomics / Economic / Outcomes Research Information Elements of Pharmaceutical/Biotech Pricing I - Introduction

Faculty: Jack Mycka, President, Optimar Strategic Consulting LLC, Montclair, NJ, USA; Renato Dellamano PhD, President, ValueVector (Value Added Business Strategies), Milan, Italy

Course Description: This course gives an understanding of the key terminology and issues in pharmaceutical pricing decisions. It covers the tools to build and document product value including issues, information and processes employed; the role of pharmacoeconomics and the differences in payment systems that help to shape pricing decisions. These tools are further explored through a series of interactive exercises. *This course is for those with limited experience in the area of pharmaceutical pricing and will cover topics within a global context.*

Modeling Methods Pharmacoeconomic Modeling

Faculty: Uwe Siebert, MD, MPH, MSc, ScD, Prof. & Chair, Dept. of Public Health, Medical Decision Making & HTA, UMIT, Hall/Innsbruck, Austria, & Assoc. Prof., MGH-ITA, Harvard Medical School, Boston, MA, USA; Bernhard Bornschein MD, MPH, Senior Scientist, UMIT, Hall/Innsbruck, Tyrol, Austria; Alexander Göhler MD, Senior Scientist, MGH-Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA

Course Description: This course presents in-depth discussion of advanced pharmacoeconomic modeling techniques such as Monte Carlo analysis, Markov modeling, and probabilistic sensitivity analysis including a review of the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations. *This course is for those with intermediate experience with modeling techniques.*

Real World Data Methods European Databases & Retrospective Database Analysis

Faculty: TBD
Course Description: Large administrative patient databases provide an opportunity to examine retrospectively the effects of health care intervention use on clinical and economic outcomes in "real world" settings. During this course, databases in Europe and their characteristics are discussed. Issues when conducting retrospective database analysis will be examined. The ISPOR Checklist for Retrospective Database Studies, a useful tool for assessing / conducting retrospective studies, is discussed. *This course is for those with little experience with European databases and retrospective database analysis.*

Quality of Life / Patient-Reported Outcomes / Preference-Based Methods Application of Item Response Theory in Patient Outcomes Measurement

Faculty: TBD
Course Description: Item Response Theory (IRT) measures the mathematical relationship between an examinee ability and item response to attain more accurate readings of actual aptitude/conceptions of health-related devices and issues. This course highlights the background of IRT and discusses its applications in patient outcomes research. Instructors also evaluate the usefulness of IRT in comparison with other patient outcomes measures. *This course is designed for those with little experience with IRT.*

SATURDAY, 28 October 2006
(Afternoon) 13:00 - 17:00

Use of Pharmacoeconomics / Economic / Outcomes Research Information

Case Studies in Pharmaceutical/Biotech Pricing II - Advanced
Faculty: Jack Mycka, President, Optimar Strategic Consulting LLC, Montclair, NJ, USA; Renato Dellamano PhD, President, ValueVector (Value Added Business Strategies), Milan, Italy

Course Description: Case studies will be employed to lead participants through the key steps of new product pricing, with focus on the need to thoroughly analyze the business environment and its constraints and

opportunities and the need to closely integrate the pricing, reimbursement and PE strategy for the new product with the clinical development and marketing strategies. *This course is for individuals who have completed Elements of Pharmaceutical Pricing I - Introduction or are familiar with both the key determinants of pharmaceutical pricing and the main international health systems.*

Modeling Methods Bayesian Methods in Economic Evaluations

Faculty: TBD
Course Description: This course provides an overview of the Bayesian approach and its application to health economics and outcomes research. The course covers basic elements of Bayesian statistics, discusses differences between Bayesian and classical approaches, and demonstrates how to apply the Bayesian approach to clinical trials and cost-effectiveness analyses. Available software is discussed, and examples of studies are presented. *This course is for those with a basic appreciation of statistics and probability.*

Quality of Life / Patient-Reported Outcomes / Preference-based Methods Utility Measurements (Preference-Based Techniques)

Faculty: Jan Busschbach PhD, Senior Investigator, Department for Medical Psychology and Psychotherapy and Erasmus Medical Center, Rotterdam, The Netherlands; Ely Stolk MSc, Institute for Medical Technology Assessment (IMTA), Erasmus University Medical Center Rotterdam, The Netherlands

Course Description: Utility measurement determines an individual's preference for a certain outcome represented by a quantitative score. During this course, methods for measuring preference-based outcomes will be demonstrated. To equip participants in the field of utility measurement, the most important issues are discussed: we consider potential insensitivity of generic instruments for particular disease specific problems, and to what extent adaptation of generic or disease-specific QoL instruments offer a solution. This will be demonstrated with an exercise. Also the issue of "whose values count: patient values or values from the general public?" will be discussed. *This course is for those with some experience with QoL measures in health economic evaluation.*

Instrument Development & Evaluation for Patient- Reported Outcomes Assessment

Faculty: Andrew Lloyd M. Phil, Research Scientist and Deputy Director, United BioSource Health Care Analytics Group - Europe, London, UK; and Patricia van Hanswijk de Jonge PhD, MSc, Senior Research Associate, Health Care Analytic Group, United BioSource Corporation, London, UK
Course Description: PRO instrument development and evaluation includes psychometric analyses including the use of factor analysis, and other techniques. The course will cover the recent draft guidance from the FDA as well as existing guidance from the EMEA regarding instrument development. *This course is designed for those with some experience with using PRO instruments.*

SUNDAY, 29 October 2006
(Morning) 8:00 - 12:00

Pharmacoeconomic / Economic Methods Transferability of Cost-Effectiveness Data between Countries

Faculty: Michael Drummond PhD, Professor of Health Sciences, University of York, York, UK; Andrea Manca PhD, MSc, Wellcome Trust Fellow in Health Services Research, Centre for Health Economics, University of York, York, UK; Marco Barbieri MSc, Associate Lecturer and Research Associate, University Pompeu Fabra and i3 Innovus, Barcelona, Spain; Samuel Aballea MS, Research Analyst, i3 Innovus, High Wycombe, UK
Course Description: Clinical trials are done in international settings to quickly recruit a sufficient number of patients and to have at least some economic data from multiple countries. However, decision-makers require country-specific or region-specific data on health care costs and only accept foreign or international data when translated to their own specific setting. This course discusses factors making economic data more difficult to transfer between countries than clinical data. Then we review the methods that have been presented to offer a solution to this problem and their pros and cons. *This course is for those with basic understanding of cost calculation and modeling.*

Cost-Effectiveness Analysis alongside Clinical Trials

Faculty: Scott Ramsey MD, PhD, Full Member, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Henry Glick PhD, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA

Course Description: Growing numbers of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory / reimbursement requirements of many countries that consider evidence of economic value along with clinical efficacy. This course presents the design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials based on, in part, the Good Research Practices for Cost-Effectiveness Analysis alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Trial design, selecting data elements, database design and management, analysis, and results reporting are presented. Trials evaluating effectiveness and clinical outcome measures are discussed. Obtaining health resource use and health state utilities directly from study subjects and economic data collection fully integrated into the study are discussed. Analyses guided by an analysis plan and

hypotheses, an incremental analysis using an intention to treat approach, characterization of uncertainty, and standards for reporting results are presented. *This course is introductory/intermediate. Familiarity with economic evaluations will be helpful.*

Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies

Faculty: C. Daniel Mullins PhD, Professor and Chair of Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA

Course Description: This course describes methods to determine costs associated with a health condition and the budget impact of new technologies for that condition. The course presents incidence and prevalence based costing strategies. Treatment algorithms and event-based approaches are demonstrated for disease-specific costs from different decision-maker perspectives. Static and dynamic methods for estimating the budget impact of adding a new drug to a health plan formulary are presented. Issues related to imputing missing data are also discussed. *This course is for those with some experience with PE analysis.*

Use of Pharmacoeconomic / Economic / Outcomes Research Information

Health Care and Reimbursement Systems in Europe

Faculty: Arie Rietveld MD, MBA, Senior Principal, Cambridge Pharma Consultancy, a unit of IMS, Cambridge, UK

Course Description: This course describes and compares various European health care systems, and includes information on health care financing and resource allocation mechanisms. Various issues encountered when defining benefit packages or introducing new health care technology are discussed. The course covers newer developments in European health care system organization and management, such as provision and purchaser-provider splits, including a discussion of the current role of health technology assessment and health economic analysis for reimbursement decisions in Europe. Participants apply course contents in a country-specific case study. *This course is for those with little experience with health care systems and reimbursement in Europe.*

Modeling Methods Pharmacoeconomic Modeling - Advanced

Faculty: Uwe Siebert, MD, MPH, MSc, ScD, Prof. & Chair, Dept. of Public Health, Medical Decision Making & HTA, UMIT, Hall/Innsbruck, Austria, & Assoc. Prof., MGH-ITA, Harvard Medical School, Boston, MA, USA; Bernhard Bornschein MD, MPH, Senior Scientist, UMIT, Hall/Innsbruck, Tyrol, Austria; Alexander Göhler MD, Senior Scientist, MGH-Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA

Course Description: This course reviews modeling techniques and their application in a "real world" setting. It discusses the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations and evaluates its implications for the application of various modeling methods. Using examples, the course carefully reviews the practical steps involved in developing and using these models and in the selection and modeling of data inputs and practical aspects related to the determination of when, why and how to handle stochastic and probabilistic uncertainty. Participants will have hands-on activities. *This course follows the short course, "Pharmacoeconomic Modeling", and is designed for those with intermediate / advance knowledge of modeling methods.*

Discrete Event Simulation for Economic Analyses

Faculty: J. Jaime Caro MDCM, FCRPC, FACP, Scientific Director, Caro Research Institute, Concord, MA, USA; Jürgen Möller MSc, Mech Eng, Simulation Specialist, Caro Research Institute, Concord, MA, USA

Course Description: This course provides basic understanding of key DES concepts, focusing on the use of simulation models to address pharmacoeconomic (and device-related) problems. The course is structured around practical exercises. Topics are: Why DES? Dynamic simulation as a tool; Components of a DES; How do you build a model? Modeling of processes and resource use; modeling of variables and decisions; and the ISPOR Task Force Reports on Good Research Practices - Modeling Studies / Cost-Effective Analysis alongside Clinical Trials. Participants should bring their laptops. After the course, participants understand how to interpret the results of a DES, using simulation as a tool, and can map simple dynamic processes in ARENA. *This course is designed for those with some experience with modeling.*

Quality of Life / Patient-Reported Outcomes / Preference-based Methods Analysis and Interpretation of Quality of Life and Patient- Reported Outcomes

Faculty: TBD
Course Description: This course provides a range of methods that may help solve common problems encountered with QoL/PRO, including an overview of psychometric validation methods (including a brief overview of Rasch analysis), missing data analysis techniques, and methods to assess minimally clinically important differences. This course discusses the ISPOR co-developed report: "Incorporating the Patient's Perspective Into Drug Development And Communication Report" and the Principles of Good Practice for the Translation and Cultural Adaptation Process for PRO Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Specific examples are used. *This course is for those with little experience with QoL studies.*

ISPOR 9th Annual European Congress

28-31 OCTOBER 2006 / COPENHAGEN, DENMARK



PROGRAM

"ASKING CRITICAL QUESTIONS"

Saturday, 28 October 2006

8:00-17:00 ISPOR Pre-Congress Short Courses

Sunday, 29 October 2006

8:00-12:00 ISPOR Pre-Congress Short Courses

12:00-13:00 Grand Opening, Exhibits & Contributed Poster Presentations Viewing - Session I

13:00-13:30 WELCOME FROM THE ISPOR PRESIDENT

Michael Drummond PhD, Professor of Health Economics, University of York, Heslington, York, UK

INTRODUCTION AND CONGRESS OBJECTIVES

Ivar Sønbo Kristiansen MD, MPH, PhD, Professor, Institute of Health, University of Oslo, Oslo, Norway

13:30-15:00 FIRST PLENARY SESSION: "HEALTH TECHNOLOGY ASSESSMENT (HTA) AS A BASIS FOR REIMBURSEMENT AND PRIORITIES IN HEALTH CARE"

Moderator: Bengt Jönsson PhD, Professor of Health Economics, Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden

13:30-13:40 Introduction

Speaker: Bengt Jönsson PhD, Professor of Health Economics, Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden

13:40-14:10 HTA as a Basis for Reimbursement and Priorities in Health Care: European and Industry Perspective

Speaker: Richard Bergström MScPharm, Managing Director, Swedish Association of the Pharmaceutical Industry, Stockholm, Sweden

14:10-14:40 HTA as a Basis for Reimbursement and Priorities in Health Care: Government and Nordic Perspective

Speaker: Audun Hagaa MSc, Deputy Director General, Ministry of Health and Care Services, Oslo, Norway

14:40-15:00 Panel Discussion

15:00-15:30 Break, Exhibits & Contributed Poster Presentations Viewing - Session I

15:30-16:30 Contributed Workshops Session I

ECONOMIC STUDY METHODS

W1: DRG-BASED CASE COSTS: WHY THEY ARE NOT COMPARABLE ACROSS BORDERS AND SHOULD BE USED WITH CAUTION

DISCUSSION LEADER: Judith A. O'Brien, RN, BSPA, Vice President & Director of Cost Research, Caro Research Institute, Concord, MA, USA

W2: THEORETICAL & PRACTICAL ISSUES IN THE CALIBRATION OF PHARMACO-ECONOMIC MODELS

DISCUSSION LEADERS: Douglas CA. Taylor, MBA, Director, Health Economics and Outcomes Research, i3 Innovus, Medford, MA, USA; Denise Kruzikas, PhD, U.S. Health Outcomes, GlaxoSmithKline, Philadelphia, PA, USA; David Thompson, PhD, Vice President, Global Health Economics, i3 Innovus, Medford, MA, USA

HEALTH CARE POLICY

W3: COMBINING DIRECT AND INDIRECT COMPARISONS TO PROVIDE PRODUCT VALUE ARGUMENTS

DISCUSSION LEADERS: Jeroen P Jansen, PhD, Senior Project Manager, Mapi Values, Houten, The Netherlands; Keith Tolley, MS, Director, Mapi Values, Bollington, Cheshire, UK

W4: REIMBURSEMENT OF DRUGS IN GERMANY - A ROAD MAP FOR THE APPROVAL PROCESS

DISCUSSION LEADER: Hubertus Rosery, Dr, MPH, BA, Senior Associate, Analytica International, Lörrach, Germany

CLINICAL STUDY METHODS/RISK ASSESSMENT

W5: META-ANALYSIS OF COMPLEX DATA VIA MIXED MODELS: TOOLS FOR SYNTHESIZING EVIDENCE-BASED MEDICINE

DISCUSSION LEADER: Mireya Diaz, PhD, Assistant Professor, Case Western Reserve University, Cleveland, OH, USA

PATIENT-REPORTED OUTCOMES METHODS (INCLUDING COMPLIANCE & PREFERENCE STUDIES)

W6: VALUING EQ-5D HEALTH STATES: PAST PRACTICE AND FUTURE POSSIBILITIES
DISCUSSION LEADERS: Paul Kind, Principal Investigator, University of York, York, UK; Frank De Charro, Executive Director, EuroQoL Group, Rotterdam, The Netherlands; BA Van Hout, PhD, Professor, University Medical Center Utrecht, Utrecht, The Netherlands

W7: MEASUREMENT GUIDED MEDICATION MANAGEMENT IN IMPROVING ADHERENCE WITH PRESCRIBED DRUG DOSING REGIMENS IN AMBULATORY CARE

DISCUSSION LEADERS: John Urquhart MD, Professor, UCSF, Palo Alto, CA, USA; Bernard Vrijens, PhD, Chief Scientist, Pharmionic Systems, Vise, Liege, Belgium

16:30-17:00 Break, Exhibits & Contributed Poster Presentations Viewing - Session I

17:00-18:00 Contributed Workshops Session II

ECONOMIC STUDY METHODS

W8: DESIGN ISSUES FOR HEALTH ECONOMICS IN POST-LAUNCH REAL WORLD STUDIES

DISCUSSION LEADERS: Mike Drummond, DPhil, Professor of Health Economics, University of York, York, Heslington, UK; Deborah Marshall, PhD, Vice President, Global Health Economics and Outcomes, i3 Innovus, Burlington, ON, Canada; Daniela Belovich, MSc, Project Manager, i3 Innovus, Burlington, ON, Canada

W9: DEVELOPING ECONOMIC MODELS: PREDICTING CHANGE OVER TIME WITH FRACTIONAL POLYNOMIALS

DISCUSSION LEADERS: K. Jack Ishak, PhD, Statistician, Caro Research Institute, Montreal, QC, Canada; J. Jaime Caro, MDCM, FRCPC, FAC, President & Scientific Director, Caro Research Institute, Concord, MA, USA; Irina Proskorovsky, BSc, Statistician, Caro Research Institute, Dorval, QC, Canada

HEALTH CARE POLICY

W10: THE IMPACT OF ADMINISTRATIVE COSTS RESULTING FROM PRESCRIPTION RESTRICTIONS ON THE COST-EFFECTIVENESS OF INNOVATIVE PHARMACEUTICALS

DISCUSSION LEADERS: Mark JC Nuijten, MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands; Ken Redekop, PhD, Scientist, IMTA, Rotterdam, The Netherlands

CLINICAL STUDY METHODS/RISK ASSESSMENT

W11: NEW DEVELOPMENTS IN DATA MINING: DIGGING INTO OBSERVATIONAL DATABASES AND ITS USE IN DRUG SAFETY SURVEILLANCE

DISCUSSION LEADERS: Charles M Gerrits, MS, PharmD, PhD, Head - Global Pharmacoepidemiology & Outcomes Research, Takeda Global Research & Development, Lincolnshire, IL, USA; Andrew Bate, MA, PHD, Manager - Research Methodologies, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden; Manfred Hauben, MD, MPH, Medical Director - Risk Management Strategy, Pfizer Inc, New York, NY, USA

W12: COMMONALITIES AND DISSIMILARITIES BETWEEN EUROPEAN OBSERVATIONAL DATASETS

DISCUSSION LEADERS: John Parkinson, PhD, Head GPRD, MHRA, MHRA, London, UK, UK; Miriam Sturkenboom, PhD, Associate Professor, Erasmus University Medical Centre, Rotterdam, The Netherlands; Tjeerd P Van Staa, MD, PhD, Head of Research, General Practice Research Database, London, UK

PATIENT-REPORTED OUTCOMES METHODS (INCLUDING COMPLIANCE & PREFERENCE STUDIES)

W13: QUANTIFYING PHYSICIAN AND PATIENT WILLINGNESS TO ACCEPT RISK-BENEFIT TRADEOFFS: HOW TO COMPARE APPLES AND ORANGES

DISCUSSION LEADERS: F. Reed Johnson, PhD, Senior Fellow and Principal Economist, RTI International, Research Triangle Park, NC, USA; Brett Hauber, PhD, Senior Director, Health Economics, RTI International, Research Triangle Park, NC, USA; Josephine Mauskopf, PhD, Vice President, RTI Health Solutions, RTP, NC, USA

W14: QUANTIFICATION OF HEALTH STATES WITH MULTIDIMENSIONAL SCALING

DISCUSSION LEADER: Paul Krabbe, PhD, Senior Researcher, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands

18:00-20:00 Exhibitors' Open House Reception, Contributed Poster Presentations Viewing - Session I

18:00-19:00 Author Presentation Hour

Monday, 30 October 2006

8:00-9:00 Exhibit & Contributed Poster Presentations Viewing - Session II

9:00-10:30 SECOND PLENARY SESSION: EVIDENCE BASED MEDICINE (EBM): TIME FOR ASKING CRITICAL QUESTIONS

Moderator: Kjeld Møller Pedersen PhD, Professor of Health Economics and Health Policy Department of Public Health, Health Economics, University of Southern Denmark, Odense C, Denmark

9:00-9:10 Introduction

Speaker: Kjeld Møller Pedersen PhD, Professor of Health Economics and Health Policy Department of Public Health, Health Economics, University of Southern Denmark, Odense C, Denmark

9:10-9:40 EBM - Time for Asking Critical Questions?

Speaker: Ivar Sønbo Kristiansen MD, PhD, MPH, University of Oslo, Institute of Health Management and Health Economics, Oslo, Norway

9:40-10:10 EBM - Emerging Reality and Assorted Myths

Speaker: Paul Glasziou MD, Professor, University of Oxford, Department of Primary Health Care Old Road Campus, Oxford, UK

10:10-10:30 Panel Discussion

10:30-10:45 Break, Exhibits & Contributed Poster Presentations Viewing - Session II

10:45-11:45 Contributed Podium Presentations - Session I

DIABETES

DB1: RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS

Sturkenboom MC¹, Dieleman JP², Van der Lei J², ¹Erasmus University Medical Center, Soest, The Netherlands, ²Erasmus University Medical Center, Rotterdam, The Netherlands

DB2: INSULIN THERAPY AMONG TYPE 2 DIABETES PATIENTS: IMPACT OF CONVERSION TO A PEN DEVICE ON ADHERENCE, HYPOGLYCEMIC EVENTS, AND COSTS

Lee WC¹, Balu S², Cobden D³, Joshii AV³, Pashos CL², ¹Abt Associates Inc, Bethesda, MD, USA, ²Abt Associates Inc, Lexington, MA, USA, ³Novo Nordisk Inc, Princeton, NJ, USA

DB3: GLYCEMIC RESPONSE TO NEWLY INITIATED ANTIHYPERGLYCEMIC THERAPIES IN A LARGE MANAGED CARE ORGANIZATION

Karter AJ, Moffet HH, Ahmed AT, Liu JY, Go AS, Selby JV, Kaiser Permanente, Oakland, CA, USA

DB4: SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A UNITED STATES THIRD-PARTY PAYER SETTING

Palmer AJ¹, Minshall ME², Valentine WJ¹, Foss V¹, Tunis SL², ¹IMS, Allschwil, Switzerland, ²IMS, Fishers, IN, USA

ECONOMIC STUDIES I

ES1: COST-UTILITY ANALYSES OF NEW MEDICAL TECHNOLOGIES: OFTEN COST-EFFECTIVE, SOMETIMES COST-INEFFECTIVE, DOMINANT, OR DOMINATED, BUT ALMOST NEVER "DECREMENTALLY" COST-EFFECTIVE.

Kent DM¹, Cohen JT¹, Fendrick AM², Langa KM², Neumann PJ³, ¹Tufts-New England Medical Center, Boston, MA, USA, ²University of Michigan, Ann Arbor, MI, USA, ³Tufts University School of Medicine, Boston, MA, USA

ES2: DIRECT MEDICAL COSTS OF SOLID ORGAN TRANSPLANT IN BRITISH COLUMBIA, CANADA

Levy AR¹, Sobolev B², James D³, Sullivan SD⁴, Partovi N⁵, Barrable W⁵, Levy R⁵, ¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³St Paul's Hospital, Vancouver, BC, Canada, ⁴University of Washington, Seattle, WA, USA, ⁵BC Transplant Society, Vancouver, BC, Canada

ES3: PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY: IMPACT ON CASE-RELATED TREATMENT COSTS

Brecht JG¹, Mueller K², Welte R³, Schädlich P⁴, ¹InForMed GmbH, Ingolstadt, Bavaria, Germany, ²Sana-Krankenhaus Riegen, Bergen, Mecklenburg-Vorp, Germany, ³GlaxoSmithKline, Munich, Germany, ⁴InForMed GmbH, Itzehoe, Schleswig-Holste, Germany

ES4: SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSES

Muszbec N, Hutton J, United BioSource Corporation, London, UK

GI DISORDERS

GI1: COST OF FUNCTIONAL DYSPEPSIA – RESULTS FROM A LARGE US EMPLOYER DATABASE

George S¹, Kleinman N², Brook R³, Smeeding J⁴, ¹Conexus Health, Tampa, FL, USA, ²The HCMS Group, Cheyenne, WY, USA, ³The JeSTARx Group, Newfoundland, NJ, USA, ⁴The JeSTARx Group, Dallas, TX, USA

GI2: DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS: NESTED CASE CONTROL STUDY

Höer A¹, Gothe H¹, Mangiapane S¹, Sterzel A², Grass U³, Häussler B¹, ¹IGES GmbH, Berlin, Germany, ²ALTANA Pharma GmbH, Konstanz, Germany, ³ALTANA Pharma Deutschland GmbH, Konstanz, Germany

GI3: COST-UTILITY ANALYSIS IN A UK SETTING OF VASOACTIVE DRUG TREATMENTS IN ACUTE BLEEDING OESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS – A DISCRETE EVENT SIMULATION MODEL

Wechowski JG¹, Tetlow AP¹, McEwan P¹, Woehl A¹, Currie CJ², ¹Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ²Cardiff University, Cardiff, South Glamorgan, UK

GI4: COST-EFFECTIVENESS OF TRIPLE THERAPIES OF ESOPEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI ERADICATION IN THE PUBLIC SECTOR OF HONG KONG

Lee KK, Lee VVY, Chan FK, The Chinese University of Hong Kong, Shatin, Hong Kong, China

INDIVIDUAL'S HEALTH

IH1: PATIENTS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT

Monzini MS¹, De Portu S², Baranzoni N³, Scalone L¹, Giannetti A³, Mantovani LG², ¹University of Milan, Milan, Milan, Italy, ²University of Naples, Federico II, Naples, Naples, Italy, ³Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Modena, Italy

IH2: HEALTH OUTCOMES FOR MOTHERS OF DISABLED AND CHRONICALLY ILL CHILDREN

Lethbridge L, Burton P, Phipps S, Dalhousie University, Halifax, NS, Canada

IH3: FEASIBILITY AND PRIMARY VALIDITY OF A GERMAN EQ-5D CHILDREN'S VERSION

Greiner W, Universität Bielefeld, Bielefeld, Germany

IH4: METHYLPHENIDATE PRESCRIPTIONS FOR CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): NEW DATA FROM NORD-BADEN/GERMANY

Schlender M¹, Schwarz O¹, Viapiano M², Bonauer N², ¹Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, ²Kassenärztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany

11:45-12:00 Break, Exhibits & Contributed Poster Presentations - Session II

12:00-13:00 Contributed Podium Presentations - Session II

CARDIOVASCULAR I

CV1: COST-EFFECTIVENESS OF EPTIFIBATIDE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN GERMANY

Dewilde S¹, Bruggenjurgen B², Welte R³, Willich SN⁴, ¹United BioSource Corporation, Brussels, Belgium, ²Alpha Care, Celle, Germany, ³GlaxoSmithKline, Munich, Germany, ⁴Charite University Medical Center, Berlin, Germany

CV2: RECURRENT INFREQUENT UNEXPLAINED PALPITATIONS (RUP) STUDY: COMPARISON OF IMPLANTABLE LOOP RECORDER VERSUS CONVENTIONAL DIAGNOSTIC TESTING

Giada F¹, Raviele A¹, Ponzi P², Colangelo I², ¹Umberto I Hospital, Mestre-Venice, Venice, Italy, ²Medtronic Italia, Sesto San Giovanni, Milan, Italy

CV3: COST-EFFECTIVENESS OF INTENSIVE STATIN THERAPY COMPARED TO MODERATE STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: ANALYSIS FROM CANADA, GERMANY AND THE UK

Drummond MF¹, Schwartz JS², Koren M³, Cannon C⁴, Davie A⁵, Shui A⁴, Murphy S⁴, Graff J⁶, ¹University of York, York, Heslington, UK, ²University of Pennsylvania, Merion Stn, PA, USA, ³Memorial Hospital, Jacksonville Heart Center, Jacksonville Center for Clinical Research, Jacksonville, FL, USA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ⁵Novo, Uxbridge, Middlesex, UK, ⁶Pfizer, Inc, New York, NY, USA

CV4: ASSESSING COST-EFFECTIVENESS BEFORE MARKETING: A CASE-STUDY OF RIMONABANT FOR REDUCTION OF CARDIOMETABOLIC RISK IN PATIENTS WITH DYSLIPIDEMIA IN THE UK

Caro JJ¹, Getsios D², Proskorovsky I³, Nicholls C⁴, McEwan P⁵, ¹Caro Research Institute, Concord, MA, USA, ²Caro Research Institute, Halifax, NS, Canada, ³Caro Research Institute, Dorval, QC, Canada, ⁴Sanofi-Aventis, Guildford, Surrey, UK, ⁵Cardiff Research Consortium, Cardiff, UK

METHODS & CONCEPTS I

MC1: GROWTH, CHARACTERISTICS, AND QUALITY OF THE COST-UTILITY LITERATURE THROUGH 2003

Palmer JA¹, Cohen JT², Cochran GL³, Eldar-Lissai A⁴, Greenberg D⁵, Lavelle TA⁶, Wang ST⁷, Neumann PJ², ¹Tufts-New England Medical Center, Boston, MA, USA, ²Tufts University School of Medicine, Boston, MA, USA, ³University of Nebraska Medical Center, Omaha, NE, USA, ⁴University of Rochester, Rochester, NY, USA, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶Harvard University, Cambridge, MA, USA, ⁷Harvard School of Public Health, Boston, MA, USA

MC2: 15DS – A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS

Soini EJ¹, Ryyänänen OP², ¹Department of Health Policy and Management, Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ²General Practice, Department of Public Health and Clinical Nutrition, University of Kuopio, Kuopio, Finland

MC3: USING SIMULATIONS TO EXPLORE THE INFLUENCE OF COMPETING RISK ON TREATMENT-EFFECT

Kent DM¹, Hayward RA², ¹Tufts-New England Medical Center, Boston, MA, USA, ²University of Michigan, Ann Arbor, MI, USA

MC4: BREAKING THE SILENCE: THE EFFECTS OF EXPLICIT INSTRUCTIONS ON INCORPORATING INCOME IN TTO EXERCISES

Krol M¹, Brouwer W¹, Sendi P², ¹The Institute for Medical Technology Assessment, Rotterdam, The Netherlands, ²Institute for Clinical Epidemiology, Basel, Switzerland

PATIENT REPORTED OUTCOMES

PR1: HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES OF BREAST CANCER

Lidgren M¹, Wilking N¹, Jönsson B², Rehnberg C¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Stockholm, Sweden

PR2: ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. DATA OF VALIDITY OF THE SF-6D VS EQ-5D IN SPAIN.

Rebollo P¹, Moris J¹, Ortega F², Valdés C², ¹BAP Health Outcomes, Oviedo, Asturias, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

Program continued inside >

PROGRAM CONTINUED...

PR3: LOW ADHERENCE WITH GASTROPROTECTIVE AGENTS WHEN CO-PRESCRIBED WITH NSNSAIDS ASSOCIATED WITH INCREASING RISK OF GI-RELATED HOSPITALISATION

Koncz T, Lister S, Makinson G, Pfizer Limited, Tadworth, Surrey, UK

PR4: PREFERENCES OF PEOPLE WITH DIABETES FOR INHALED AND INJECTABLE INSULIN REGIMENS

Chancellor J¹, Aballéa S¹, Lawrence A², Sheldon R², Cure S¹, Plun-Favreau J³, i3 Innovus, Uxbridge, Middlesex, UK, ²Accent, London, UK, ³Pfizer Ltd, Tadworth, UK

SCHIZOPHRENIA

SZ1: EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN ROUTINE CARE

Stargardt T¹, **Weinbrenner S**¹, Busse R¹, Juckel G², Gericke CA³, ¹Berlin University of Technology, Berlin, Germany, ²Ruhr University School of Medicine, Bochum, Germany, ³The University of Adelaide, Adelaide, Australia

SZ2: TREATMENT PERSISTENCE WITH DIFFERENT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA

Ren X¹, Kazis L², Qian S², ¹Center for Health Quality, Outcomes, and Economic Research, Bedford, MA, USA, ²Boston University, Boston, MA, USA

SZ3: PREDICTORS OF GAF CHANGES IN AUSTRALIANS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): INTERIM RESULTS FROM THE E-STAR STUDY

Lambert T¹, Emmerson B², Hustig H³, Diels J⁴, Jacobs A⁴, Methven C⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, ³Glenside Hospital, Fullarton, South Australia, Australia, ⁴Janssen Pharmaceutica N.V, Beerse, Belgium, ⁵Janssen-Cilag Pty Ltd, North Ryde, New South Wales, Australia

SZ4: A CAREER'S PERSPECTIVE ON THE VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES USING THE ASSESSMENT OF QUALITY OF LIFE QUESTIONNAIRE AND THE EQ5D

Adams J¹, Le Reun C¹, **Crowley S**², Eggleston A³, ¹M-TAG Pty Ltd, Chatswood, NSW, Australia, ²Program Evaluation Unit, University of Melbourne; Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia, ³Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia

13:00-14:30 Lunch, Exhibits & Contributed Poster Presentations Viewing- Session II

13:30-14:30 Symposium: "The Increasing Need for Real-life Data in Observational Studies Throughout the Product Life Cycle" Sponsored by IMS Health

14:30-15:30 Contributed Podium Presentations - Session III

CARDIOVASCULAR II

CV5: PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS "NO TREATMENT" IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND

Plich A¹, Filipiak KJ¹, Splawinski J², Gumulka W¹, ¹Medical University of Warsaw, Poland, ²National Institute of Public Health, Warsaw, Poland

CV6: DIFFERENCES IN PERCENTAGE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION AND GOAL ATTAINMENT AMONG NEWLY INITIATED USERS OF STATINS IN A REAL LIFE SETTING

Heintjes E¹, Hirsch MW², O'Donnell JC², **Herings RM**¹, ¹PHARMO Institute, Utrecht, The Netherlands, ²Astra Zeneca UK Ltd, Macclesfield, Cheshire, UK

CV7: RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITAL INPATIENT ADMISSION FOR CONGESTIVE HEART FAILURE

Gemmen EK¹, Bharmal M¹, **Zyczynski T**², ¹Quintiles Strategic Research Services, Falls Church, VA, USA, ²GE Healthcare, Princeton, NJ, USA

CV8: REAL WORLD MORTALITY OF THE HYPERTENSIVE PATIENT AS DEFINED IN THE ASCOT-LLA

F Bobadilla J¹, Sicras A², Moreno R³, García Puig J⁴, García M⁵, Navarro R², Soto J¹, ¹Pfizer Spain, Alcobendas, Madrid, Spain, ²Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ³San Carlos Clinical Hospital, Madrid, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Euroclin Institute, Alcobendas, Madrid, Spain

ECONOMIC STUDIES II

ES5: RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBESE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK: AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION

Getsios D¹, Moller J², Ishak KJ³, McEwan P⁴, Danel A⁵, Caro JJ⁶, ¹Caro Research Institute, Halifax, NS, Canada, ²Caro Research Institute, Eslov, Sweden, ³Caro Research Institute, Montreal, QC, Canada, ⁴Cardiff Research Consortium, Cardiff, UK, ⁵Sanofi-Aventis, Paris, France, ⁶Caro Research Institute, Concord, MA, USA

ES6: ENTRY AND PRICE RESPONSE IN MARKETS WITHOUT PATENT PROTECTION: THE CASE OF PHARMACEUTICALS IN ARGENTINA

Maceira DA, Center for the Study of the State and Society, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

ES7: DIRECT MEDICAL COSTS OF STROKE ACCORDING TO HANDICAP LEVELS AFTER 12 AND 18 MONTHS

Bouchez M¹, Jasso Mosqueda G¹, Spieler JF², De Pourville G³, Chicoye A¹, Amarengo P², ¹Aremis-aegisnet, Neuilly sur Seine, France, ²Service de Neurologie Hôpital Bichat, Paris, France, ³Gustave Roussy Institute, Villejuif, France

ES8: TREATMENT COSTS OF DIFFERENT PHASES IN BREAST CANCER (BC) IN HUNGARY

Muszbeke N¹, Benedict A², ¹UnitedBioSource Corporation, London, UK, ²UnitedBioSource Corporation, Budapest, Hungary

OSTEOPOROSIS & ARTHRITIS

OA1: QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS TREATED WITH COMBINATION VS. SINGLE DRUG THERAPY - RESULTS FROM FIN-RACO TRIAL

Hahl J¹, Bergius S¹, Sintonen H², Hannonen P³, Korpela M⁴, Leirisalo-Repo M⁵, Hakala M⁶, Möttönen T⁷, ¹GlaxoSmithKline Oy, Espoo, Finland, ²University of Helsinki, Helsinki, Finland, ³Jyväskylä Central Hospital, Jyväskylä, Finland, ⁴Tampere University Hospital, Tampere, Finland, ⁵Helsinki University Central Hospital, Helsinki, Finland, ⁶Rheumatism Foundation Hospital, Heinola, Finland, ⁷Turku University and Turku University Central Hospital, Paimio, Finland

OA2: SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES

Lyssy AE¹, Schaefer M², ¹Institut für Klinische Pharmakologie Medizinische Fakultät der Humboldt-Universität/Charité, Berlin, Germany, ²Institut für Klinische Pharmakologie, Berlin, Germany

OA3: HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

Le Pen C¹, Bergmann JF², Dougados M³, Ruszniewski P⁴, Umuhire D⁵, Chen C⁶, Kramarz P⁷, Lilliu H⁷, ¹Dauphine University, PARIS, France, ²Lariboisiere Hospital, Paris, France, ³Cochin Hospital, PARIS, France, ⁴Beaujon Hospital, CLICHY Cedex, France, ⁵AREMIS Consultants, Neuilly-sur-seine, France, ⁶Pfizer Inc, New York, NY, USA, ⁷Pfizer, Surrey, UK

OA4: A HEALTH-ECONOMIC EVALUATION OF RHBMP-2 IN SPINE FUSION SURGERY IN GERMANY AND UK

Chhabra A¹, Bentley A², Donnell D¹, Greenberg D³, Oliver E⁴, Alt V⁵, ¹Medtronic Europe Sarl, Tolochenaz, Switzerland, ²Abacus International, Bicester, UK, ³Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁴Medtronic Ltd, Watford, UK, ⁵University Hospital Giessen-Marburg, Brackenheim, Germany

RESPIRATORY DISORDERS

RS1: CAN PHARMACEUTICAL INDUSTRY USE REPS TO PROVIDE MEDICAL PRACTICE GUIDELINES? (MIGRAINE AND ASTHMA)

Chaix-couturier C¹, Benis E¹, Calles B², Collomb D¹, Anhoury P¹, ¹IMS Health, Puteaux, France, ²LIR, Paris, France

RS2: TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED

Breekveldt-Postma NS¹, Koerselman J¹, Erkens JA¹, Van der Molen T², Lammers JWJ³, **Herings RM**¹, ¹PHARMO Institute, Utrecht, The Netherlands, ²University of Groningen, Groningen, The Netherlands, ³University Medical Center Utrecht, Utrecht, The Netherlands

RS3: THE COST-EFFECTIVENESS OF TIOTROPOLIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Akobundu E¹, DeLisle S², Giangreco G³, Mullins CD¹, ¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA, ³VA Maryland Health Care System, Baltimore, MD, USA

RS4: CLINICALLY IMPORTANT FACTORS CONTRIBUTING TO COSTS OF CARE DEFINED VIA ANALYSIS OF COMPREHENSIVE PATIENT RECORDS

Palmu P¹, Reissell E¹, Schultz J¹, Rehn M¹, Pirskanen A¹, Minkkinen S¹, Salonoja M¹, Kunnas T¹, Sintonen H², Haahela T³, Lindqvist A³, Laitinen T¹, ¹GeneOS Ltd, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland

15:30-15:45 Break, Exhibits & Contributed Poster Presentations Viewing- Session II

15:45-16:45 Contributed Podium Presentations - Session IV

CANCER

CN1: TREATMENTS FOR METASTATIC MELANOMA: SYNTHESIS OF EVIDENCE FROM RANDOMIZED TRIALS

Einarson TR¹, Lui P¹, Cashin R¹, Machado M², Corey-Lisle P³, Hemels M⁴, ¹University of Toronto, Toronto, ON, Canada, ²Universidad de Chile, Santiago, RM, Chile, ³Bristol-Myers Squibb, Wallingford, CT, USA, ⁴Bristol-Myers Squibb, Braine-L'Alleud, Belgium

CN2: USING PSYCHOMETRIC AND CLINIMETRIC TECHNIQUES TO SELECT ITEMS FOR USE IN A NEW INSTRUMENT TO MEASURE CANCER-RELATED FATIGUE

Baro E¹, Carulla J², Valentín V³, Rodríguez C⁴, Gascón P⁵, García-Mata J⁶, Colomer R⁷, Cassinello J⁸, Herdman M¹, Gasquet JA⁹, Sánchez J⁹, ¹3D Health Research, Barcelona, Spain, ²Hospital de Vall d'Hebrón, Barcelona, Spain, ³Hospital 12 de octubre, Madrid, Spain, ⁴Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁵Hospital Clinic i Provincial de Barcelona, Barcelona, Spain, ⁶Hospital Santa Maria Nai, Orense, Spain, ⁷ICO Girona, Girona, Spain, ⁸Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁹Amgen S.A, Barcelona, Spain

CN3: PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

Pompen M¹, Novak A¹, Postmus P², Gok M², Gylmark M³, ¹Roche Nederland B.V, Woerden, The Netherlands, ²VU University Medical Center, Amsterdam, The Netherlands, ³F Hoffmann La Roche, Basel, Switzerland

CN4: COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK

Lewis G¹, Morlotti L², Creeden J³, Gyldmark M³, Peake MD⁴, ¹Roche Products Limited, Welwyn Garden City, Herts, UK, ²Analytica Int, Loerrach, Germany, ³F Hoffmann La Roche, Basel, Switzerland, ⁴Glenfield Hospital, Leicester, UK

HEALTH CARE USE & POLICY STUDIES

HP1: CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS: A SYSTEMATIC REVIEW

Gumbs PD¹, Verschuren WMM², Mantel-Teeuwisse AK¹, De Wit GA², De Boer A¹, Klungel OH¹, ¹Utrecht University, Utrecht, The Netherlands, ²National Institute for Public Health and the Environment, Bilthoven, The Netherlands

HP2: TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK

Blak BT¹, Mullins CD¹, Simoni-Wastila L¹, Shaya FT¹, Cooke CE², Weir MR¹, ¹University of Maryland, Baltimore, MD, USA, ²Pfizer Inc, Ellicott City, MD, USA

HP3: THE ROLE OF GENERAL PRACTITIONERS IN THE INITIAL MANAGEMENT OF WOMEN WITH URINARY INCONTINENCE IN FRANCE, GERMANY, SPAIN AND THE UK

O'Donnell M¹, Hunskaar S¹, Viktrup L², ¹University of Bergen, Bergen, Norway, ²Eli Lilly and Company, Indianapolis, IN, USA

HP4: SUMMARIZING POPULATION HEALTH USING EQ-5D

Chuang LH, Kind P, University of York, York, UK

INFECTION

IN1: BUDGETARY IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINATION OF NEWBORNS IN THE PERSPECTIVE OF THE REGIONAL HEALTHCARE SYSTEM OF LOMBARDY

Berto P¹, Principi N², ¹Pbe consulting, Verona, Italy, ²Università di Milano, Fondazione IRCCS "Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena", Milano, Italy

IN2: EUROPEAN SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION (ESAC): DEVELOPING VALID ANTIBIOTIC PRESCRIBING QUALITY INDICATORS FOR AMBULATORY CARE

Ferech M, Coenen S, Goossens H, University of Antwerp, Antwerp, Belgium

IN3: RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL THERAPY AND THE COST-EFFECTIVENESS OF ANTIRETROVIRAL THERAPY

Habib MJ¹, Lawson K², Summers KK³, Eakin RT², Barner J², Brown C², Shepherd MD², ¹i3 Innovus, Burlington, ON, Canada, ²University of Texas at Austin, Austin, TX, USA, ³South Texas Veterans Health Care System, San Antonio, TX, USA

IN4: MEDICAL MANAGEMENT AND COSTS ASSOCIATED WITH STAPHYLOCOCCUS AUREUS (SA) BACTERAEMIA IN HAEMODIALYSIS PATIENTS: A COST-OF-ILLNESS STUDY

Strens D¹, Moeremans K¹, Annemans L¹, Jadoul M², Cambier P³, ¹IMS HEOR, Brussels, Belgium, ²Cliniques Universitaires St Luc, Brussels, Belgium, ³CHR Citadelle, Liège, Belgium

METHODS & CONCEPTS II

MC5: HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS: RESULTS FOR GERMANY FROM A MULTI-COUNTRY CROSS-SECTIONAL STUDY

Zlateva G¹, Xu X², Lenz C³, Pauleikhoff D⁴, ¹Pfizer Inc, New York, NY, USA, ²Covance Market Access Services, Gaithersburg, MD, USA, ³Pfizer Pharma GmbH, Germany, Karlsruhe, Germany, ⁴Augenarztpraxis des St. Franziskus-Hospital, Münster, Germany

MC6: HOW DO THE SCORES OF GENERIC HRQL INSTRUMENTS REFLECT THE DIRECT TO VALUATIONS OF OWN HEALTH BY GENERAL POPULATION?

Kotomäki T, Honkalampi T, Sintonen H, University of Helsinki, Helsinki, Finland

MC7: TRANSLATION AND VALIDATION OF NEW LANGUAGE VERSIONS OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE

Doward LC¹, McKenna SP¹, Meads DM¹, Twiss J¹, Revicki D², Wong R³, Luo MP⁴, ¹Galen Research, Manchester, UK, ²Center for Health Outcomes Research, Bethesda, MD, USA, ³Abbott, Parsippany, NJ, USA, ⁴Abbott, Abbott Park, IL, USA

MC8: THE COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS. ACCOUNTING FOR MEDICAL COSTS IN LONGER LIFE EXPECTANCIES

Feenstra TL, Van Baal P, Hoogenveen R, Vijgen SM, Bemelmans WJ, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

16:45-17:00 Break, Exhibits & Contributed Poster Presentations Viewing- Session II

17:00-18:00 ISPOR FORUMS

- BIOTECHNOLOGY COUNCIL FORUM
- MEDICATION COMPLIANCE & PERSISTENCE SIG FORUM
- ECONOMIC DATA TRANSFERABILITY GOOD RESEARCH PRACTICES TASK FORCE FORUM
- DRUG COST GOOD RESEARCH PRACTICES TASK FORCE FORUM

18:00-19:30 Exhibitors' Wine & Cheese Reception & Poster Presentations Viewing - Session II

18:00-19:00 Author Presentation Hour

20:00-21:30 RECEPTION at the COPENHAGEN

TOWN HALL – ISPOR Networking Event

Open to all congress registrants. Invitation letters found in your registration packet are required for entrance. Reception compliments of the Copenhagen City Council & transportation compliments of ISPOR. (Buses will depart the Radisson SAS Falconer beginning at 19:30 and will run continuously until 22:30.)

Tuesday, 31 October 2006

8:00-9:00 Exhibits & Contributed Poster Presentations Viewing - Session III

9:00-10:00 Issues Panels - Session I

HEALTH POLICY

IP1: MEETING PROPOSED FDA STANDARDS FOR PATIENT REPORTED OUTCOMES (PROS); ARE THEY ACHIEVABLE?

Moderator: John Brodersen, MD, GP, PhD, University of Copenhagen, Copenhagen, Denmark
Panelist(s): Svend Kreiner, MSc, Associate Professor, University of Copenhagen, Copenhagen, Denmark; **Lynda Doward, MRes**, Associate Director of Research, Galen Research, Manchester, UK; **Alan Tennant, BA, PhD**, Professor of Rehabilitation Studies, The University of Leeds, Leeds, UK

HEALTH CARE REIMBURSEMENT / COVERAGE ISSUES

IP2: THE NATIONAL INSTITUTE OF HEALTH AND CLINICAL EXCELLENCE (NICE) SINGLE TECHNOLOGY APPRAISAL (STA) PROCESS: AN UPDATE ON THE FIRST ROUND OF SUBMISSIONS

Moderator: Shahnaz Khan, MPH, Director, Reimbursement Dossier Services, RTI Health Solutions, RTP, NC, USA

Panelist(s): Carole Longson, PhD, Director, NICE, London, UK; **Sorrel Wolowacz, PhD**, Senior Health Economist, RTI-Health Solutions, Manchester, UK; **Mark J Sculpher, PhD**, Professor, University of York, York, UK

USE OF HEALTH ECONOMIC/ PHARMACOECONOMIC INFORMATION BY DECISION-MAKERS ISSUES

IP3: DO ECONOMISTS HAVE ANYTHING TO CONTRIBUTE TO HEALTH ECONOMICS?

Moderator: Joakim Ramsberg, PhD, Health Economist, Pharmaceutical Benefits Board, Solna, Sweden

Panelist(s): Bengt Liljas, PhD, Value Demonstration Leader, AstraZeneca, Mölndal, Sweden; **F. Reed Johnson, PhD**, Senior Fellow and Principal Economist, Research Triangle Institute, Research Triangle Park, NC, USA; **Peter Zweifel, PhD**, Professor, University of Zurich, Zurich, Switzerland

10:00-10:30 Break, Exhibits & Contributed Poster Presentations Viewing- Session III

10:30-11:30 Issues Panels - Session II

HEALTH CARE REIMBURSEMENT / COVERAGE ISSUES

IP4: ARE INTERVENTIONS TO INFLUENCE UTILIZATION AND COSTS OF PHARMACEUTICALS COST-EFFECTIVE?

Moderator: Kjeld Møller Pedersen, PhD, Professor, University of Southern Denmark, Odense C, Denmark
Panelist(s): Ivar S. Kristiansen, MD, PhD, MPH, Professor, University of Oslo, Oslo, Norway; **Douglas Lundin, PhD**, Health Economist, LFN Pharmaceutical Benefits Board, Solna, Sweden; **Eivind Jorgensen, MPhil**, Health Economics Manager, AstraZeneca Norway, Oslo, Norway

HEALTH POLICY ISSUES

IP5: RISK-BENEFIT AND PHASED RELEASE: A NEW PARADIGM FOR RISK MANAGEMENT AND ACCELERATED APPROVAL?

Moderator: Adrian Towse, MPhil, Director, Office of Health Economics, London, UK

Panelist(s): Louis P. Garrison, PhD, Professor, University of Washington, Seattle, WA, USA; **Nicky Lilliott**, Director of Regulatory Affairs, ABPI, London, UK

PHARMACOECONOMIC / HEALTH ECONOMIC STUDY METHODOLOGY ISSUES

IP6: EVENT BASED ANALYSIS FOR ECONOMIC ANALYSIS: SENSIBLE RESPONSE TO REDUCE NOISE OR DANGEROUS VIOLATION OF THE RANDOMISATION PRINCIPLE?

Moderator: Andrew Briggs, DPhil, Professor, University of Glasgow, Glasgow, UK

Panelist(s): Mark J Sculpher, PhD, Professor, University of York, York, UK

11:30-13:00 Lunch, Exhibits & Contributed Poster Presentations Viewing- Session III

12:00-13:00 Author Presentation Hour

13:00-14:20 THIRD PLENARY SESSION: SOCIETAL VALUE OF A QALY

Moderator: Ivar Sønbo Kristiansen MD, PhD, MPH, University of Oslo, Institute of Health Management and Health Economics, Oslo, Norway

13:00-13:10 Introduction

Speaker: Ivar Sønbo Kristiansen MD, PhD, MPH, University of Oslo, Institute of Health Management and Health Economics, Oslo, Norway

13:10-13:40 Looking for Willingness to Pay (WTP) Threshold for a QALY-- Does it make sense? -- A Critical View

Speaker: Dorte Gyrd-Hansen PhD, Professor, University of Southern Denmark, Institute of Public Health, Odense, Denmark

13:40-14:10 Looking for Willingness to Pay (WTP) Threshold for a QALY Does it make sense? -- A Practical View

Speaker: Martin Buxton BA (Soc Sci), Professor, Brunel University Health Economics Research Group, Uxbridge, Middlesex, UK

14:10-14:20 Panel Discussion

14:20-14:30 Contributed Research Award Presentations

14:30-14:45 Break, Exhibits & Contributed Poster Presentations Viewing- Session III

14:45-15:45 Contributed Workshops Session III

ECONOMIC STUDY METHODS

W15: PRICE, AVAILABILITY AND AFFORDABILITY OF CHRONIC DISEASE MEDICINES

DISCUSSION LEADERS: Richard Laing, MBChB, MSc, MD, Medical Officer, World Health Organization, Geneva, Switzerland; Margaret Ewen, Dip, Pharm, Principal, Global Projects, Health Action International Europe, Amsterdam, The Netherlands; Susanne Gelders, MSc, Technical Officer, World Health Organization, Geneva, Switzerland

W16: SHOULD THE LOWER COST OF GENERICS OR PARALLEL IMPORTS BE APPLIED TO ECONOMIC EVALUATIONS?

DISCUSSION LEADERS: Donald Macarthur, BSc, Senior Consultant, PriceSpective Limited, Buntingford, Hertfordshire, UK; Keiron Sparrowhawk, MSc, MBA, Principal, PriceSpective Limited, Buntingford, Hertfordshire, UK; Stephen Beard, MSc, Head of Health Economics, RTI Health Solutions, Manchester, UK

HEALTH CARE POLICY

W17: THE IMPLICATIONS OF REQUIREMENTS FOR SUBPOPULATION ANALYSES: THE DUTCH EXPERIENCE

DISCUSSION LEADERS: Mark JC Nuijten, MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands; Carin Uyl-de Groot, PhD, Professor, IMTA, Rotterdam, The Netherlands; Frans Rutten, PhD, Professor, IMTA, Rotterdam, The Netherlands

CLINICAL STUDY METHODS/RISK ASSESSMENT

W18: ACCOUNTING FOR MULTIPLE HEALTH STATES IN COMPETING RISK CALCULATIONS IN ECONOMIC EVALUATION: A CASE STUDY IN ATHEROTHROMBOTIC DISEASE

DISCUSSION LEADERS: Kristen Migliaccio-Walle, BS, Senior Researcher, Caro Research Institute, Concord, MA, USA; H. Baris Deniz, MSc, Researcher, Caro Research Institute, Concord, MA, USA; J. Jaime Caro, MDCM, FRCPC, FAC, President & Scientific Director, Caro Research Institute, Concord, MA, USA

W19: TESTING AND CORRECTING FOR ENDOGENEITY IN ESTIMATING TREATMENT EFFECTS

DISCUSSION LEADERS: Henry Joe Henk, PhD, Researcher, i3 Magnifi, An Ingenix Company, Eden Prairie, MN, USA; William Crown, PhD, President, i3 Innovus, Auburndale, MA, USA

PATIENT-REPORTED OUTCOMES METHODS (INCLUDING COMPLIANCE & PREFERENCE STUDIES)

W20: HEALTH OUTCOMES STRATEGIES TO BRIDGE CLINICAL AND MARKETING OBJECTIVES

DISCUSSION LEADERS: Meryl Brod, PhD, President, The Brod Group, Mill Valley, CA, USA; Torsten Christensen, MSc, Senior Health Economist, Novo Nordisk, Bagsvaerd, Denmark

W21: THE WHAT AND WHO OF HEALTH OUTCOMES MEASUREMENT: INTERSECTION OF TYPES OF OUTCOMES AND SOURCES OF REPORTS

DISCUSSION LEADERS: Judith T. Barr, ScD, Director, NERCOA, Northeastern University, Boston, MA, USA; Pennifer Erickson, PhD, President, OLGA, Pennsylvania State University, State College, PA, USA

15:45-16:00 Break, Exhibits & Contributed Poster Presentations Viewing- Session III

16:00-17:00 Contributed Workshops Session IV

ECONOMIC STUDY METHODS

W22: ADJUSTING FOR BASELINE HEALTH CARE RESOURCE USE AND HEALTH RELATED QUALITY OF LIFE IN PROSPECTIVE COST-EFFECTIVENESS STUDIES - WHEN AND HOW?

DISCUSSION LEADERS: Deborah Marshall, PhD, Vice President, Global Health Economics and Outcomes, i3 Innovus, Burlington, ON, Canada; Dan Pericak, MMath, Senior Manager, i3 Innovus, Burlington, ON, Canada; William Crown, PhD, President, i3 Innovus, Auburndale, MA, USA

W23: STRUCTURAL SENSITIVITY ANALYSIS WITH DES

DISCUSSION LEADERS: Jorgen Moller, MSc, Arena Specialist, Caro Research Institute, Concord, MA, USA; H. Baris Deniz, MSc, Researcher, Caro Research Institute, Concord, MA, USA; J. Jaime Caro, MDCM, FRCPC, FAC, President & Scientific Director, Caro Research Institute, Concord, MA, USA

HEALTH CARE POLICY

W24: REIMBURSEMENT RESTRICTIONS IN GERMANY DUE TO REFERENCE PRICES

DISCUSSION LEADERS: Olaf Pirk, MD, Principal, Fricke & Pirk GmbH - Member of the IMS Health Group, Nuernberg, Germany; Martin Voelkl, MSc, Senior Consultant, Fricke & Pirk GmbH - Member of the IMS Health Group, Nuernberg, Germany

W25: EARLY ASSESSMENT OF NEW AND EMERGING PHARMACEUTICALS TO SUPPORT HEALTH CARE DECISION-MAKING

DISCUSSION LEADERS: Karla Douw, MSc, HTA Consultant, University of Southern Denmark, Odense, Denmark; Sue Simpson, PhD, Research Fellow, University of Birmingham, Birmingham, UK; Birgitte Bonnevie, MSc, HTA Consultant, National Board of Health, Copenhagen, Denmark

CLINICAL STUDY METHODS/RISK

W26: NUMBER NEEDED TO TREAT: MISLEADING, MISUNDERSTOOD, MISUSED?

DISCUSSION LEADERS: Jørgen Nexøe, PhD, General Practitioner, Senior Researcher, University of Southern Denmark, Odense, Denmark; Peder Halvorsen, PhD-student, General Practitioner, University of Southern Denmark, Odense, Denmark; Palle Mark Christensen, PhD, Clinical Pharmacologist, University of Southern Denmark, Odense, Denmark; Ivar S. Kristiansen, MD, PhD, MPH, Professor, University of Oslo, Oslo, Norway

PATIENT-REPORTED OUTCOMES METHODS (INCLUDING COMPLIANCE & PREFERENCE STUDIES)

W27: THE COSTS AND BENEFITS OF COMPLIANCE MEASUREMENT FOR ALL STAKE-HOLDERS IN HEALTH CARE

DISCUSSION LEADERS: Mark JC Nuijten, MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands

W28: USING REAL WORLD DATA TO FOLLOW UP REIMBURSEMENT DECISIONS

Discussion Leaders: Andreas Engstrom, MSc, Health Economist, LFN Pharmaceutical Benefits Board, Solna, Sweden; Gepke Delwel, PhD, Policy Advisor, CVZ Health Care Insurance Board, Diemen, The Netherlands; Johan Brun, MD, Medical Director, Pfizer AB, Sollentuna, Sweden

ACPE Continuing Education: For pharmacists (CPE): Continuing Education credits for pharmacists will be provided by Trinka Medical Publications. Attendees can earn up to 16 hours (1.6 CEUs) for attending Issues Panels, Forums, Plenary Sessions, Workshops, and Podium Sessions at the ISPOR 9th Annual European Congress, up to 4 hours (0.4 CEUs) for each half-day short course, and up to 7.5 hours (0.75 CEUs) for each full day short course. Trinka Medical Publications is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. **Instructions:** To receive continuing education credit, obtain the Continuing Education Program Summary Booklet at the ISPOR registration desk OR register online at <https://www.ispor.org/members/events/9thEuro/DisplayEvent.aspx> (you will receive the Summary Booklet in your registration packet). Complete the information requested and return the entire Continuing Education Program Summary Booklet to the ISPOR registration desk at the end of the meeting. Certificates of participation will be sent 4 - 6 weeks after the completion of the program to participants who register and complete the program evaluation. **The fee for this service is \$30 USD.**



Congress Promotional Opportunities:

Exhibit *Register now for exhibit space!*

Over 1300 attendees in 2005! Present your products and services to key outcomes researchers and health care decision-makers in pharmaceutical, medical device & diagnostics, biotechnology industries, clinical practice, government agencies, academia, and health care organizations.

Benefits to Exhibitors:

- Listing & 1/4 page advertisement in the Program & Schedule of Events
- Listing & 1/4 page advertisement on the ISPOR website
- One complimentary registration per exhibit booth
- Pre-registrant mailing labels

Sponsor *Increase your visibility!*

Give your company increased visibility and prominence.

Benefits to Sponsors:

- Sponsorship recognition at plenary session
- Event signage
- Listing & 1/4 page advertisement in the Program & Schedule of Events
- Listing & 1/4 page advertisement on the ISPOR website
- One complimentary registration per booth
- Preferential exhibit booth location

Advertise

Advertise in the Program & Schedule of Events!

ALL ADVERTISEMENTS MUST BE RECEIVED BY 7 SEPTEMBER 2006 TO BE INCLUDED IN THE PROGRAM & SCHEDULE OF EVENTS

Employment: *Targeted employment assistance!*

ISPOR's Professional Recruitment Assistance Program (PRAP) provides participants with a CONFIDENTIAL, EFFICIENT, and PROFESSIONAL service which matches individuals seeking positions with employers who have available positions.

PRAP Includes: • List of available positions • List of qualified candidates • Interview Room • Confidential mailbox system for applicants and employers

• 1/4 page employment advertisement in the Program & Schedule of Events • List of 9th Annual European Congress PRAP positions at the ISPOR website



For detailed Congress and promotional information, visit the ISPOR website: www.ispor.org

ISPOR 9TH ANNUAL EUROPEAN CONGRESS REGISTRATION

28-31 OCTOBER 2006 / RADISSON SAS FALCONER HOTEL AND CONFERENCE CENTER / COPENHAGEN, DENMARK

please print clearly

Member ID# _____

NAME				DEGREES	
POSITION				ORGANIZATION	
MAILING ADDRESS					
CITY	STATE	ZIP	COUNTRY		
TELEPHONE	FAX	EMAIL			

ISPOR SHORT COURSE REGISTRATION

SATURDAY, 28 OCTOBER 2006

ALL DAY 8:00-17:00

Pharmacoeconomics for Decision-Makers

MORNING SESSIONS 8:00-12:00

Elements of Pharmaceutical/Biotech Pricing I - Intro

Pharmacoeconomic Modeling

Retrospective Database Analysis

Application of Item Response Theory in Patient Outcomes Measurement

AFTERNOON SESSIONS 13:00-17:00

Case Studies in Pharmaceutical/Biotech Pricing II - Advanced

Bayesian Methods in Economic Evaluations

Utility Measurements (Preference-Based Techniques)

Instrument Development & Evaluation for PRO

SUNDAY, 29 OCTOBER 2006

MORNING SESSIONS 8:00-12:00

Transferability of Cost-Effectiveness Data between Countries

Cost-Effectiveness Analysis alongside Clinical Trials

Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies

Health Care and Reimbursement Systems in Europe

Pharmacoeconomic Modeling - Advanced

Discrete Event Simulation for Economic Analyses

Analysis and Interpretation of QoL/PRO

SHORT COURSE REGISTRATION FEES

HALF DAY COURSES

BEFORE 19 SEPTEMBER 2006

US\$150 124 € REGULAR FEE

US\$75 62 € STUDENT FEE

AFTER 19 SEPTEMBER 2006

US\$200 165 € REGULAR FEE

US\$100 83 € STUDENT FEE

FULL DAY COURSES

BEFORE 19 SEPTEMBER 2006

US\$300 248 € REGULAR FEE

US\$150 124 € STUDENT FEE

AFTER 19 SEPTEMBER 2006

US\$400 331 € REGULAR FEE

US\$200 165 € STUDENT FEE

ISPOR CONGRESS REGISTRATION

exchange rate as of January 2006

ISPOR Member Non-Member*

Standard

Registration Before 19 September US\$600 496 € US\$740 612 €

Registration After 19 September US\$700 579 € US\$840 695 €

Clinical Practitioners (Clinical Practice, Hospital)

Registration Before 19 September US\$450 372 € US\$590 488 €

Registration After 19 September US\$550 455 € US\$690 571 €

Full-Time Government and Academia

Registration Before 19 September US\$300 248 € US\$440 364 €

Registration After 19 September US\$400 331 € US\$540 447 €

ISPOR Member Non-Member*

Full-Time Students (must provide current enrollment documentation)

Registration Before 19 September US\$100 83 € US\$135 112 €

Registration After 19 September US\$150 124 € US\$185 153 €

One Day Registration (per day)** (One Day registrations cannot be combined)

29 Oct 30 Oct 31 Oct US\$350 289 € US\$400 331 €

Continuing Education Accreditation US\$30 25 € US\$30 25 €

REGISTRATION FEES

	QTY	FEE	TOTAL
Short Course Full Day Registration			
Short Course Half Day Registration			
Congress Registration			
Reception at the Town Hall of Copenhagen*		\$0.00	\$0.00

*Monday 30 October 20:00-21:30

TOTAL REGISTRATION FEE:

PAYMENT INFORMATION

Please enclose a check payable in US dollars or Euro € to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to: VISA MasterCard American Express ACCOUNT NUMBER: _____ EXPIRATION DATE: _____

NAME: _____ AUTHORIZED SIGNATURE: _____

Mail Details: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research, 3100 Princeton Pike, Building 3 Suite E, Lawrenceville, New Jersey 08648, USA Tel: 1-609-219-0773 Fax: 1-609-219-0774 • E-Mail: info@ispor.org • Internet: www.ispor.org

Payment Details: Payment may be made by check, travelers check, bank transfer (there is a USD \$40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-US checks written in US\$ on banks with a US counterpart are at no charge. For Non-US checks written in US\$ on banks with NO US counterpart there is USD \$25 charge. Phone charges will NOT be accepted.

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. For bank transfers, please designate

the registration name and/or registration number.

Membership Details:

- If ISPOR cannot verify your current membership, you will be charged the non-member registration rate.
- When you register as a non-member, you receive an ISPOR membership which includes a one-year online subscription to *VALUE IN HEALTH* - The Journal of the International Society for Pharmacoeconomics and Outcomes Research.
- One day registration does not include ISPOR membership benefits and cannot be combined.

Cancellation Details: Cancellation fee before 19 September 2006 is US \$100. No refunds given after 19 September 2006.

Online registration available at www.ispor.org